RenalFDA Approved

Terlipressin

Intravenous

Overview

A synthetic vasopressin analog and prodrug that is cleaved by endopeptidases to release lysine-vasopressin. Terlipressin has greater V1a receptor selectivity than vasopressin, producing splanchnic vasoconstriction that reduces portal pressure and redistributes blood flow to the kidneys.

Mechanism of Action

This mechanism addresses the pathophysiology of hepatorenal syndrome (HRS) by counteracting the splanchnic vasodilation that drives renal hypoperfusion..

Research Summary & Key Findings

FDA-approved in 2022 (Terlivaz) for hepatorenal syndrome type 1. CONFIRM trial demonstrated significant improvement in renal function (verified HRS reversal in 32% vs. 17% with placebo) without the need for renal replacement therapy (Wong et al., NEJM, 2021). Previously approved in Europe and Asia for variceal bleeding and hepatorenal syndrome. Risk of respiratory failure prompted a boxed warning in the FDA label.

Clinical Status

FDA Approved

Terlipressin has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

Related Peptides in Renal

Vasopressin (ADH)

FDA Approved

A nine-amino acid cyclic peptide hormone (arginine vasopressin) produced in the hypothalamus and released from the poste...

View details

Desmopressin (DDAVP)

FDA Approved

A synthetic analog of vasopressin with enhanced V2 receptor selectivity and minimal V1a vasopressor activity. Desmopress...

View details

Find a Provider

Find a verified provider who offers Terlipressin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Terlipressin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.